spacer
home > epc > spring 2002 > annual review of contract research organisations
PUBLICATIONS
European Pharmaceutical Contractor

Annual Review of Contract Research Organisations

The total number of CROs has continued to increase in 2001 in spite of economic conditions that the CROs describe as 'tough'; globally we record 25 more CROs than at this time in 2000. The greatest growth has been of European clinical CROs, while the number of clinical CROs in North America has actually fallen marginally (see Figures 1 and 2) for the first time. In Table 1 we compare the total number of CROs in 2001 with the number in 1980. Over this 21-year period the average year-on-year growth has been 6.5 per cent (a slight increase from 2000). This increase has been driven by clinical CRO growth over the period, which has averaged 11.1 per cent in Europe and 8.4 per cent in North America.

he near double-digit growth in the number of CROs contrasts with that for contract packers and manufacturers (CPMs) which has averaged 3.6 per cent globally with almost equal growth in North America and Europe.

The deceleration of the rate of growth of CROs is clearly illustrated by the graphs of the three-year moving average of the number of additional CROs, in existence (the average of each of the three previous years' number of additional CROs), which we have plotted in Figures 3-5. In all three fields - clinical, preclinical and CPMs - the average growth rate has fallen to well below its peak level seen in and around the 1990 period.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Graham Hughes, Scientific Director of Technomark Consulting Services Ltd, and Marianne O'Neill, Manager of Technomark Research

Graham Hughes is Scientific Director and a Founder of Technomark Consulting Services Limited. Over the last 15 years he has keenly observed the evolving CRO scene and seen it grow from something of a cottage industry into a global US$8 billion industry. He is also the Scientific Investment Director of Technomark Medical Ventures, a novel consulting partnership with Lloyds Development Capital, which is responsible for investing in early stage life science companies and nurturing them as they grow.

Marianne O'Neill's responsibilities include the management of the database system upon which the Technomark Registers and other Technomark publications are dependent.

She also undertakes various data gathering and market intelligence assignments on behalf of external customers as well as providing research support to all the other divisions of Technomark Consulting Services Ltd. Marianne co-ordinates the Technomark Registers Online and the Technomark Website.


spacer
Dr Graham Hughes
spacer
spacer
spacer
Marianne O'Neill's
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Prince Helps Sustainable Pharma Packaging Pioneers Woolcool Celebrate 10th Anniversary

Ground-breaking sustainable pharma packaging firm Woolcool celebrated a decade of innovation with a visit by HRH The Prince of Wales.
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement